Últimas noticias sobre Tilray Brands (NASDAQ:TLRY) Bolsa

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Tilray Brands Inc

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has risen 6.81% since its last report. The company recently reported that it has 133.89 million shares sold short, which is 14.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738251018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 13.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Tilray Brands's Recent Short Interest

As Prime Minister Justin Trudeau prepares to step down, Canada&#8217;s <a href="https://www.benzinga.com/cannabis">cannabis industry</a> faces a turning point that could redefine its future. Trudeau's government not only legalized recreational cannabis in 2018, but also positioned Canada as a global leader in marijuana reform, being the first G7 nation to federally legalize cannabis for both medical and adult use. However, the possibility of a new government under Conservative leader Pierre Poilievre introduces concerns about policy stagnation and regulatory rollbacks, raising questions about what's next for this multi-billion-dollar industry.
<h3 class="wp-block-heading">A Legacy Of Legalization</h3>
Trudeau's role in legalizing cannabis has been transformational. As Deepak Anand, principal of British Columbia-based ASDA Consultancy Services, wrote in an opinion piece for <a href="https://mjbizdaily.com/trudeau-departure-is-a-turning-point-for-canadas-cannabis-industry/?utm_campaign=MJBizDaily&amp;utm_medium=email&amp;_hsenc=p2ANqtz--TumbF3n9k5BpRIZG7sq1elN6AqpLc6Tz6h5Y-rxsHhezsVCb2eunNFxbze0rWVlmKKZndySfirNQ3TZaaf4TlIPcY99TZmvdDmeH8k_dvYP9dYOI&amp;_hsmi=343983401&amp;utm_content=343983277&amp;utm_source=hs_email">MJBizDaily</a>, legalization &#8220;not only transformed the nation's social and economic landscape but also established it as a global pioneer in marijuana reform.&#8221; Indeed, a <a href="https://leger360.com/wp-content/uploads/2024/02/PostMedia_CPC-Leadership_Trudeau_July2022.pdf">survey</a> by Leger found that 62% of Canadians support legalization, with many identifying it as one of Trudeau's most significant accomplishments.
Over the past six years, Canada's cannabis industry has generated thousands of jobs, created substantial tax revenue and solidified the country's reputation as a cannabis trailblazer. Yet, as Anand warns, &#8220;storm clouds are gathering on the horizon.&#8221;
<h3 class="wp-block-heading">Risks Under Conservative Leadership</h3>
Anand's analysis highlights the potential risks a Conservative government could bring. Specifically, he points to possible cuts to Health Canada's Controlled Substances and Cannabis Branch, which oversees industry regulations and employs over 200 staff members. &#8220;A Conservative government focused on reducing federal spending could target this department for cuts, potentially creating bottlenecks in licensing processes, amendments, and export license approvals,&#8221; he noted.
Delays in addressing key regulatory reforms, such as marketing restrictions and THC limits on edibles, could make it harder for licensed producers to compete with the illicit market and international competitors. Additionally, Anand noted the stalled progress on expanding CBD sales channels into pharmacies and health food stores, a missed opportunity in tapping into the growing global CBD market.
<h3 class="wp-block-heading">Implications for Publicly Traded Cannabis Companies</h3>
For major players in the cannabis industry like Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) and Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>), the uncertainty surrounding Canada's regulatory future could have significant financial implications. Regulatory bottlenecks might hinder these companies' ability to innovate or expand into new markets, while unresolved challenges with THC caps and marketing limitations could affect product appeal and profitability.
Tilray, for instance, has diversified operations into beverages and international markets to offset domestic challenges, but any policy rollback in Canada could limit further opportunities. Similarly, Canopy Growth's strategy to streamline operations and focus on premium products might face headwinds if reform stagnates. Aurora Cannabis, already grappling with financial restructuring, might find it even harder to gain ground without regulatory clarity.
<h3 class="wp-block-heading">The Path Forward</h3>
Anand calls for collective industry action to safeguard Canada's cannabis legacy. He urges stakeholders to proactively engage with policymakers, educate the public and push for reforms to enhance competitiveness and sustainability. &#8220;Cannabis legalization should be viewed as an ongoing process that requires continuous improvement, not as an event having come and gone,&#8221; Anand said.
The stakes are high. Failure to address the industry's needs could jeopardize economic gains, compromise patient access and diminish Canada's standing as a global cannabis leader. For the government, there's a clear imperative: advance reforms before the next election or risk being blamed for creating an unsustainable industry.
As Canada's cannabis industry braces for change, its future will largely depend on the ability of industry leaders and policymakers to work together. Whether under Liberal or Conservative leadership, the need for continuous regulatory improvement remains essential to maintaining Canada's competitive edge in the global cannabis market.
Photo of Justin Trudeau via <a href="https://commons.wikimedia.org/wiki/File:REUNI%C3%93N_CON_JUSTIN_TRUDEAU,_PRIMER_MINISTRO_DE_CANAD%C3%81,_05_DE_MARZO_DE_2024-3.jpg">Wikimedia Commons</a>, edited on Canva.

Cannabis

Can Canada Maintain Its Cannabis Edge After Trudeau's Departure?

Safe &amp; Smart Florida, the group behind Florida&#8217;s failed attempt to legalize recreational cannabis in November 2024, has <a href="https://smartandsafeflorida.com/">launched a new initiative</a> to do it again in a 2026 ballot.
The "Adult Personal Use of Marijuana," initiative was filed on Tuesday, first <a href="https://floridapolitics.com/archives/715832-recreational-pot-supporters-launch-fresh-campaign-to-put-new-measure-on-the-ballot/">reported</a> by Florida Politics, noting that it was the first ballot petition filed in 2025.
The new initiative "Allows adults 21 and older to possess, purchase, or use marijuana for non-medical consumption. Establishes possession limits. Prohibits marketing and packaging attractive to children. Prohibits smoking and vaping in public. Maintains prohibition on driving under influence,&#8221; and more. 
Florida Politics pointed out that the campaign launched this new effort to put legal marijuana up for a vote just one day after Gov. <a href="https://www.benzinga.com/topic/ron-desantis" target="_blank" rel="noreferrer noopener">Ron DeSantis</a> called a special session asking lawmakers to crackdown on &#8220;fraudulent signatures&#8221; to place amendments on the ballot. Leaders of the legislature, per the outlet, said they do not intend to allow DeSantis &#8220;to dictate what issues are ultimately considered by lawmakers.&#8221;
This past November, the ballot measure, known as Amendment 3, <a href="https://www.benzinga.com/markets/cannabis/24/11/41763514/florida-rejects-cannabis-legalization-amendment-supported-by-trump-detested-by-desantis">fell short </a>of the 60% vote required to pass an amendment in Florida though it received nearly 57% support across the state. The amendment faced tough and sustained opposition from DeSantis&nbsp;and the Florida Republican Party.
Over the course of its efforts, Smart &amp; Safe&#8217;s legalization campaign pulled in at least $150 million, making it the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/06/39565658/desantis-anti-cannabis-florida-freedom-fund-raises-barely-a-fraction-of-legalization-committees-" target="_blank" rel="noreferrer noopener">best-funded cannabis legalization</a>&nbsp;initiative in U.S. history, with medical marijuana giant&nbsp;Trulieve Cannabis Corp. (OTC:&nbsp;TCNNF) contributing the bulk of it.
<h1 class="wp-block-heading">Cannabis Stocks Respond</h1>
Cannabis stocks, which had dropped slightly on news that the DEA hearings on rescheduling cannabis <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">were put on hold</a> for three months, seemed to perk up a bit with the Florida initiative news.
ETFs such as AdvisorShares Pure US Cannabis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) rose 0.29% and AdvisorShares Pure Cannabis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>) went up 0.87% at the close. Trulieve Cannabis ended down 2.23% while Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) rose 0.28%. Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) held steady. Other multi-state operators seemed unfazed by the news, at least for now.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">DEA Judge Cancels Marijuana Rescheduling Hearing Amid &#8216;Disturbing&#8217; Allegations Of Improper Conduct</a></li>
</ul>
Photo: El Planteo

Government

Regulations

Politics

Legal

ETFs

GTBIF

MSOS

TCNNF

YOLO

Cannabis Legalization Headed For The Ballot Again In Florida: Advocates Launch New Amendment Initiative

AAWH

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AUSAF

AVTBF

AYRWF

BBRRF

BHHKF

BLOZF

BMMJ

CANN

CBDY

CBMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CHOOF

CLSH

CLVR

CNBS

CNBX

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVHIF

CVSI

CWBHF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

EMOR

ETST

EVIO

FFLWF

FFNTF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FLGC

FLOOF

FLWPF

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

GABRIELLAS KITCHEN INC by Gabriella's Kitchen Inc.

GABLF

GBHPF

GENE

GHBWF

GLASF

GNLN

GRAMF

GRNH

GRWG

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

HBOSF

HEMP

HERTF

HHPHF

HMLSF

IIPR

INCR

INLB

ISODIOL INTERNATIONAL ORD by Isodiol International Inc.

ISOLF

ITHUF

IVITF

JWCAF

KALY

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LFCOF

LFLY

LIFD

LMLLF

LNLHF

LOVFF

LRSNF

LVRLF

LXLLF

MAPS

MGCLF

MGWFF

MJNE

MJUS

MMNFF

MPXOF

MRMD

NDVAF

NOBDF

NWVCF

OILFF

PHOT

PKPH

FDA Solicits Public Comments On Use Of Cannabis-derived Products In Veterinary Medicine

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has risen 5.88% since its last report. The company recently reported that it has 121.20 million shares sold short, which is 13.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883010_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 13.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Tilray Brands's Recent Short Interest

The cannabis industry saw significant developments this week, with key updates from New York, New Jersey, Tilray, DoorDash, Ukraine, Agrify, Safe Harbor, the DEA and Canopy USA shaping the landscape. Here&#8217;s a closer look at the highlights.
<h3 class="wp-block-heading">New York Cannabis Industry Reports $1 Billion In 2024 Sales</h3>
New York's Office of Cannabis Management (OCM) released its 2024 annual report, showing robust growth despite a rocky start. Cannabis retailers in the state achieved nearly $1 billion in sales for 2024, supported by the issuance of 1,394 adult-use licenses, 52% of which were granted to Social and Economic Equity (SEE) applicants. The state opened 156 dispensaries, contributing over $64 million in tax revenue.
Looking ahead, the OCM aims to have 625 dispensaries operational by the end of 2025. To enhance transparency and accessibility, it launched the Legal Online Cannabis Activities Locator (LOCAL) Map, helping residents locate legal dispensaries and track license applications. However, challenges persist, including lawsuits from operators opposing recent regulatory changes and ongoing competition from unlicensed markets.
More details on <a href="https://www.cultivated.news/p/new-york-billion-cannabis-market">Cultivated</a>.
<h3 class="wp-block-heading">New Jersey Outpaces New York</h3>
Neighboring New Jersey's cannabis market reported $1 billion in sales for 2024, a 25% year-over-year increase. The Cannabis Regulatory Commission (CRC) attributed the growth to consumer trust and economic opportunities. 
"This momentum sets a solid foundation for continued success in the years ahead," <a href="https://www.cultivated.news/p/move-over-ny-nj-s-got-a-billion-dollar-cannabis-market">said</a> Chris Riggs, acting CRC director. These sales generated an estimated $43 million in tax revenue.
<h3 class="wp-block-heading">Tilray Reports Q2 2025 Financial Results</h3>
Shares of Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) traded down by double digits on Friday after the company reported its second-quarter financial results for fiscal year 2025. 
Net revenue increased by 9% to $211 million compared to $194 million in the prior year quarter, with a 10% increase on a constant currency basis. Gross profit grew 29% year-over-year to $61 million, driven by improvements across all four business segments.
Key highlights include:
<ul>
<li>Beverage alcohol revenue surged 36% to $63 million, with gross margins improving to 40%.</li>
<li>Wellness segment revenue grew 13% to $15 million.</li>
<li>International cannabis revenue increased by 25%, demonstrating Tilray's expanding global footprint.</li>
<li>Cannabis segment revenue fell slightly by 2% year-over-year to $66 million.</li>
<li>Adjusted EBITDA reached $9 million, a 10% decrease year-over-year, impacted by SKU rationalization in the beverage segment.</li>
</ul>
Tilray's Project 420, a $25 million synergy plan aimed at optimizing its beverage business, achieved $17 million in savings by the quarter's end. The company reaffirmed its fiscal year 2025 guidance, expecting net revenues between $950 million and $1 billion, ahead of consensus estimates of $900 million.
"As we enter the second half of the year, we remain committed to delivering on our financial guidance and driving shareholder value,&#8221; stated CEO Irwin Simon. &#8220;Tilray is trailblazing the future of consumer products through the infrastructure we have built, and I am enthusiastic about what lies ahead, including the potential future legalization of cannabis in the U.S."
<h3 class="wp-block-heading">DoorDash Expands Offerings To Include Hemp-Derived Products</h3>
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) announced it is now offering hemp-derived THC and CBD products, including gummies and beverages, in select states. The expansion is facilitated through partnerships with merchants like DashMart, Total Wine &amp; More, and ABC Fine Wine &amp; Spirits.
"With the growing demand for hemp-derived THC and CBD products, we're excited to expand access to a wide selection of products consumers crave," said Jacob Morello, director and general manager of alcohol and emerging categories at DoorDash. Customers can now find a "CBD/THC" tab on the app to browse hemp-derived items in states where such products are legal.
DoorDash emphasized compliance with federal laws, ensuring all products adhere to the 2018 Farm Bill's definition of hemp, which limits THC content to 0.3% by dry weight. As part of its launch, DoorDash partnered with the cannabis beverage company Cann, offering users a $2 discount on multipack purchases through the end of January.
<h3 class="wp-block-heading">Ukraine Registers Its First Medical Cannabis Product</h3>
Ukraine has taken a significant step forward in its medical cannabis program, registering the country's first approved cannabis product. The oral cannabis drops, developed in Spain, are expected to be available in pharmacies early this year. Deputy Prime Minister Olha Stefanyshyna highlighted the progress made since the legalization of medical marijuana in 2023. "The first medicines will soon appear in pharmacies."
The law legalizes medical cannabis for patients with severe illnesses and PTSD related to the ongoing conflict with Russia. Ukraine's Ministry of Health clarified that cannabis and its derivatives are no longer listed as particularly dangerous substances, allowing for controlled medical use.
President Volodymyr Zelensky, a strong advocate for medical marijuana legalization, emphasized the importance of providing relief to Ukrainians facing pain and trauma. Training programs for doctors to treat patients with cannabis are also underway as the country expands its regulatory framework.
<h3 class="wp-block-heading">Agrify Sells Cultivation Operation for $7 Million</h3>
Agrify Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>). has sold its cannabis cultivation operation to CP Acquisitions, an investment firm affiliated with former CEO Raymond Chang. The $7 million transaction includes vertical farming units, related assets and Agrify Insights software applications. Interim CEO Ben Kovler stated, "This move allows us to focus on more attractive growth categories tied to THC demand."
Agrify will now prioritize its hemp-derived THC beverage lines, including its popular Señorita THC-infused margaritas, which are sold in nine states and online.
<h3 class="wp-block-heading">Safe Harbor Eliminates $1.2 Million Liability</h3>
SHF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>), operating as Safe Harbor Financial, announced a key agreement with Partner Colorado Credit Union, eliminating $1.2 million in indemnity liability. 
CEO Sundie Seefried described the updated agreement as "a positive and pivotal development," simplifying business processes and aligning expenses with income. Safe Harbor serves more than 600 cannabis clients across 40 states and has facilitated more than $20 billion in transactions.
<h3 class="wp-block-heading">Amplify U.S. Alternative Harvest ETF To Liquidate</h3>
Amplify ETFs announced plans to liquidate its U.S. Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJUS#NYSE">MJUS</a>), ending trading on January 27. The fund's struggles reflect broader sector challenges, including the DEA's hesitance to reschedule cannabis from Schedule I. 
Cannabis ETFs like MJUS and others saw significant declines in 2024, partly due to regulatory uncertainties and limited capital access.
<h3 class="wp-block-heading">DEA Faces Scrutiny Over Cannabis Rescheduling Process</h3>
In a new twist, a DEA judge ordered the agency to respond to allegations of bias in its cannabis rescheduling hearings. Cannabis advocates argue the DEA's late submissions and alleged coordination with anti-rescheduling groups undermine the process. The DEA's cautious stance continues to impact investor confidence and industry growth.
<h3 class="wp-block-heading">Canopy USA Appoints First President</h3>
Canopy USA, a U.S.-focused entity affiliated with Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), named Brooks Jorgensen as its first president. Jorgensen, with over 25 years of leadership experience in cannabis and other high-growth industries, aims to unify the company's portfolio of brands, including Wana, Jetty and Acreage's Superflux.
"Canopy USA is a unique platform with the right combination of ingredients to deliver success," Jorgensen stated.

Earnings

AGFY

DASH

SHF Holdings, Inc. - Class A Common Stock

SHFS

The Week In Cannabis: Tilray Earnings, NY Hits $1B In Sales, DoorDash Embraces Hemp, Ukraine And More

On Friday, Tilray Brands, Inc&#8217;s. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) second-quarter net revenue increased 9% year-over-year to $210.95 million, <a href="https://www.benzinga.com//node/42908872">missing the consensus of $216.91 million.</a>
On a constant currency basis, net revenue increased by 10%.
<ul>
<li>Beverage alcohol net revenue increased 36% to $63 million.</li>
<li>Cannabis net revenue was $66 million in the second quarter compared to $67 million in the prior year quarter.</li>
<li>Distribution net revenue was $68 million in the second quarter compared to $67 million a year ago.</li>
<li>Wellness net revenue increased 13% to $15 million.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42882766/dea-accused-of-bias-in-cannabis-rescheduling-hearings-weed-stocks-plummeted-in-2024-as-process-drags-on" rel="noreferrer noopener">DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On</a>
Gross profit increased by 29% to $61 million in the second quarter compared to $47 million in the prior year quarter, with growth across all business segments. Gross margin expanded to 29% from 24% in the prior year quarter.
Adjusted gross profit increased by 20% to $63 million in the second quarter from $52 million in the prior year quarter.
Adjusted net loss per share was $(0.00) in both the second quarter and the prior year quarter <a href="https://www.benzinga.com/earnings">compared to the consensus of $(0.04).</a>
To streamline operations and boost profitability across its beverage brands, Tilray launched Project 420, which is expected to deliver $25 million in cost savings and synergies.
The beverage segment consists of a portfolio of over 20 beverage brands in different categories, including craft beer, spirits, and non-alcoholic options.
<ul>
<li>As of the second quarter, Tilray achieved $17 million of the $25 million synergy plan.</li>
<li>The company added that these savings are not completely offsetting our investment. As a result, Adjusted EBITDA for the three and six months was lower by $1.8 million and $3.2 million, respectively, due to SKU rationalization.</li>
<li>Adjusted EBITDA in the second quarter was $9 million.</li>
<li>Operating cash flow in the quarter was also lower due to these investments.</li>
<li>For the fiscal year ended May 31, 2025, the cumulative impact of these initiatives is anticipated to result in a reduction of approximately $20 million in net sales, which is expected to be offset by the growth of new product innovation, including in new beverage categories and brand extensions, over the next 18 months.</li>
</ul>
Guidance: Tilray Brands reaffirmed its 2025 fiscal year guidance of net revenues of $950 million-$1 billion <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">versus consensus of $904.85 million.</a>
Price Action: TLRY stock is down 12.8% at $1.195 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42908403/macys-shuts-down-66-locations-to-boost-profitability" target="_blank" rel="noreferrer noopener">Macy&#8217;s Shuts Down 66 Locations As Part Of New Chapter Strategy</a></li>
</ul>
Photo: Courtesy of YARphotographer via Shutterstock.

Guidance

Health Care

General

Cannabis/Beer Company Tilray Outlines Plan To Reduce Its Beverage Portfolio, Reports Mixed Q2 Earnings

WIIM

Tilray Brands shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Tilray Brands Reaffirms FY25 Guidance Of Anticipated Net Revenues Of $950M - $1B, Est $904.846M

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.04) by 97.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $210.95 million which missed the analyst consensus estimate of $216.91 million by 2.75 percent. This is a 8.87 percent increase over sales of $193.77 million the same period last year.

Earnings Beats

Earnings Misses

Tilray Brands Q2 2025 Adj EPS $(0.00) Beats $(0.04) Estimate, Sales $210.95M Miss $216.91M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) is likely to report quarterly earnings at $3.32 per share on revenue of $2.54 billion. 
• E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $161.00 million. 
• Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $226.65 million. 
• Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is expected to report quarterly earnings at $0.46 per share on revenue of $37.20 billion. 
• Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is projected to report earnings for its second quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $3.07 per share on revenue of $15.30 billion. 
• Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is projected to report quarterly earnings at $1.74 per share on revenue of $14.64 billion. 
<h3>Companies Reporting After The Bell</h3>
• WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $147.44 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETWO

NEOG

WDFC

Earnings Scheduled For January 10, 2025

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 118.71% at $3.92</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 45.83% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 26.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 17.68% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 14.29% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 8.53% at $13.18</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 7.83% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 4.26% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 3.85% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 3.74% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 3.09% at $1.48</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 22.22% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 10.07% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed down 9.84% at $4.75</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 9.53% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 8.59% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.60% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 6.57% at $2.10</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 6.28% at $2.66</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 6.26% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.52% at $1.37</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 4.69% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.64% at $0.80</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 4.23% at $0.97</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 4.02% at $1.67</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 3.94% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.59% at $1.88</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.42% at $5.07</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARA

RSSFF

SNDL

SOLCF

Cannabis Stock Movers For January 9, 2025

In a new twist on Wednesday, a DEA judge ordered the agency to respond to allegations that it opposes President Joe Biden's <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">directive of August 2023 to reschedule marijuana</a> and that it is improperly conferring with cannabis opponents. 
Marijuana Moment <a href="https://www.marijuanamoment.net/dea-judge-orders-agency-to-respond-to-new-allegations-it-opposes-marijuana-rescheduling-and-improperly-conspired-with-prohibitionists/">reported</a> that one day after a motion was filed outlining these allegations, which include improper communications with opponents of the reform, the DEA is now compelled to reply next week. Additionally, participants in the hearings are asking the judge to remove the DEA from the process, noted the outlet.
DEA Administrative Law Judge John Mulrooney <a href="https://www.dea.gov/sites/default/files/2025-01/Marijuana%20Rescheduling_Ord%20re%20Mot%20for%20Recon%20Response%20%28e%29.pdf">wrote</a> that the government is ordered to file a response to a motion to reconsider by Jan. 13. 
What Happened: Attorneys representing cannabis advocates argued the DEA&#8217;s late submission of data on marijuana reclassification undermines the fairness of the hearing process. 
They said the agency violated federal law by withholding information until the eve of the hearing, hindering the Department of Health and Human Services <a href="https://www.benzinga.com/markets/cannabis/24/01/36620822/feds-finally-release-documents-confirming-recommendation-to-reschedule-cannabis-based-on-accepte">scientific review of January 2024 </a>and depriving pro-rescheduling groups of a fair opportunity to participate.
Adding fuel to the fire, <a href="https://www.benzinga.com/markets/cannabis/24/03/37603576/dea-vs-white-house-agency-pushes-back-on-medical-benefits-of-cannabis-weed-stocks-wobble">statements from the DEA</a> have questioned the medical value of cannabis, citing a lack of robust clinical trials approved by the Food and Drug Administration to support the safety and efficacy of cannabis for its various therapeutic uses.
The original motion regarding &#8220;ex parte&#8221; communications included failing to disclose nearly 100 requests to participate in the hearings and coordinating<a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens"> with at least one anti-rescheduling group</a>.
Read Also: <a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens">DEA Slammed For Unlawful Talks With Cannabis Opponents &#8211; The Plot Thickens</a>
<h2 class="wp-block-heading">Cannabis Stocks: Deep Declines Over The Year</h2>
The reclassification process, the first of its kind since 1970, has kept cannabis industry and marijuana stocks on edge and it showed at the end of 2024. 
AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>), a benchmark for the sector, plummeted by about 48% in 2024. As of this writing, MSOS shares are down 5.91% on the day. 
U.S. and Canadian marijuana stocks didn't do much better amid concerns over the outcome of the DEA&#8217;s review.
Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) fell some 62% in 2024. Verano Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>) lost about 73%, Trulieve (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) fell about 7.5%, Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) is down 31% and Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) has lost about 37% of its value. TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTC">TSNDF</a>) was also down by 62% in 2024, while Ascend Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) dropped 64%.
Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) has fallen 45% and Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) subtracted 37%. One exception was Canada&#8217;s OrganiGram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>), which rose more than 20%.
The DEA is required to respond to the allegations by Jan. 13, so stay tuned as the process grinds on.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42805558/from-prison-to-profits-heres-how-this-entrepreneurs-cannabis-business-makes-800000-monthly">From Prison To Profits: Here&#8217;s How This Entrepreneur&#8217;s Cannabis Business Makes $800,000 Monthly</a></li>
</ul>
Image AI created.

Equities

Specialty ETFs

Small Cap

TSNDF

VRNOF

DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On

<a href="https://www.globenewswire.com/Tracker?data=u_qNa120W3fQqeVP5MaTc0ytUYiiFoOiP4_yUSbICiru5gs7-1Byz-5HQNdffdGcoXfEPBNOi9V2dXWdTeQnBvgW94jNAUPFIEnijvc8Nxo=">Tilray Medical</a>, a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>), proudly announces that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its high-quality cannabis flower. The granting of this tender by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg highlights the trust placed in Tilray Medical to deliver high-quality medical cannabis on a consistent basis across the global medical cannabis industry. Additionally, it reinforces Tilray's commitment to deliver on Europe's growing demand for premium medical cannabis products.

TSX:TLRY

Tilray Medical Wins Contract to Supply Medical Cannabis to Luxembourg

Following Surgeon General Vivek Murthy's <a href="https://www.benzinga.com/government/regulations/25/01/42787400/alcohol-increases-cancer-risk-surgeon-general-warns">Friday advisory</a> warning about cancer risks associated with alcohol consumption and calling for updates to health warning labels, Dr. Benjamin Caplan, chief medical officer at the CED Clinic in Massachusetts, Dr. Benjamin Caplan weighed in.
Caplan, a family physician with a unique focus on cannabis medicine, said Murthy's recommendations in which he cited mounting evidence of alcohol's role in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer development</a> are "a wake-up call."
The advisory &#8220;brings science in line with what many of us in medicine have long seen: alcohol isn't just a harmless social habit — it's a carcinogen," Caplan told Benzinga. 
"For some, it's a nightly ritual; for others, a way to manage stress or sleeplessness. But the damage it leaves behind is undeniable. Alcohol isn't just a drink — it's a risk factor, woven into our culture and quietly eroding our health."
Caplan gave an example of a patient who &#8220;turned to wine to unwind" and was eventually diagnosed with colon cancer. 
"Her story lingers in my mind as a reminder of how deeply alcohol is entrenched in our lives and how devastating its effects can be."
Read Also: <a href="https://www.benzinga.com/government/regulations/24/12/42724338/new-year-2025-how-americas-love-of-cannabis-transformed-social-life-industry-and-health-trends">Cannabis In 2025: Inside America&#8217;s Social, Economic, Wellness Transformation</a>
<h2 class="wp-block-heading">Changing Habits </h2>
Caplan said the challenge is not just about changing habits but about reshaping how we think.
"Alcohol is normalized to the point that alternatives — like cannabis for stress or sleep — are stigmatized or dismissed," he said. 
"But as a physician, my role is clear: to offer knowledge and compassion, to guide patients toward choices that protect their health. We owe it to our patients to meet them where they are but not leave them where they're at. The Surgeon General&#8217;s advisory is a step forward, a chance to save lives — if we're willing to listen and act."
<h2 class="wp-block-heading">Booze Stocks Tank, Cannabis Stocks Rise</h2>
As alcohol stocks drop on the Surgeon General's news, multiple cannabis stocks are on the rise for the first time in a long time.
Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is up 1.03%, Green Thumb Industries (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) up 1.65%, Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) up 2.84% and Sundial Growers Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) up 1.58%. Cresco Labs Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) is up a healthy 3.272%.
On the other hand, the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>), often viewed as a benchmark for multistate operators, is down 3.06%. Trulieve Cannabis Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) is down 5.6%. 
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42787400/alcohol-increases-cancer-risk-surgeon-general-warns">Molson Coors, Diageo, Boston Beer Tumble As Surgeon General Warns &#8216;Alcohol Consumption Increases&#8217; Cancer Risk</a>&#8216;</li>
</ul>
Photo courtesy of Dr. Ben Caplan.

Exclusives

Interview

EXCLUSIVE: Cannabis Physician Says Surgeon General's Alcohol Cancer Risk Warning Is 'Wake-Up Call'

As 2025 dawns, a cultural revolution is blooming across the United States, with cannabis emerging as a transformative force among all sectors of society. Once relegated to the shadows of illegality and stigma, cannabis now enjoys a prominent role in healthcare, <a href="https://www.benzinga.com/cannabis">industry and social life.</a>
For the first time ever, the number of Americans who consume cannabis on a nearly daily basis <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">surpassed the number of people</a> who drink that often, a shift some 40 years in the making as marijuana is now legal in some form in nearly half of all U.S. states.
<h2 class="wp-block-heading">A Decades-Long Transformation</h2>
A recent Bloomberg Intelligence survey confirms this shift, revealing that 44% of Americans now favor cannabis over alcohol, a jump from 33% just a year ago, <a href="https://www.marijuanamoment.net/analysts-see-sudden-spike-in-use-of-marijuana-as-an-alcohol-alternative/">reported</a> Marijuana Moment. This dramatic rise signals an evolution in societal attitudes, driven by wellness consciousness and a desire for alternatives to alcohol's negative health and social impacts.
Younger generations, particularly Millennials and Gen Z, are at the forefront of this change, although Baby Boomers <a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e">are also joining the trend</a>, attracted by marijuana&#8217;s therapeutic benefits.
Cannabis-derived products like CBD-infused beverages, topicals and edibles also dominate wellness markets, appealing to people of all ages.
The journey to mainstream acceptance has also been decades in the making, supported by <a href="https://www.benzinga.com/markets/cannabis/24/06/39368875/cannabis-found-less-harmful-than-alcohol-in-new-study-where-is-the-demand-heading-investor-marke">numerous studies confirming</a> that cannabis is far less harmful than alcohol. Cannabis legalization does not lead to increased fatalities on the road, according to a <a href="https://qz.com/advisor/auto-insurance/has-marijuana-legalization-made-roads-less-safe" target="_blank" rel="noreferrer noopener">study</a> using data sourced from the <a href="https://injuryfacts.nsc.org/state-data/motor-vehicle-deaths-by-state/" target="_blank" rel="noreferrer noopener">National Safety Council</a>.
Read Also: <a href="https://www.benzinga.com/24/12/42690082/trump-is-first-republican-president-with-a-pathway-to-cannabis-reform-says-former-adviser">Trump Is First &#8216;Republican President&#8217; With A Pathway To Cannabis Reform, Says Former Adviser</a>
<h2 class="wp-block-heading">Economic Ripples And Industry Adaptation</h2>
The economic impact of cannabis is undeniable. The U.S. legal cannabis market exceeded $30 billion in 2023, with <a href="https://www.benzinga.com/news/retail-sales/24/11/42193387/federal-policy-could-add-3-billion-to-cannabis-industry-on-track-to-reach-55-billion-by-2030">projections suggesting</a> it could reach $55 billion by 2030. States like California, Colorado and New York are leading the charge, fueling <a href="https://www.benzinga.com/markets/cannabis/24/04/38183087/cannabis-industry-has-created-nearly-half-a-million-full-time-jobs-new-report-reveals-which-stat">job creation</a> and innovation. Ancillary industries, ranging from packaging to marketing, are thriving. Even alcohol companies are pivoting, investing in cannabis-infused beverages to remain competitive.
Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) recently launched a series of products across its craft beer and beverage brands. The Canadian cannabis giant has been <a href="https://www.benzinga.com/markets/cannabis/23/09/34579077/tilrays-beer-business-expands-nationally-starting-in-this-state" target="_blank" rel="noreferrer noopener">buying beer brands</a> as part of its <a href="https://www.benzinga.com/markets/cannabis/23/08/33612189/tilray-acquires-8-beer-brands-from-struggling-bud-light-parent-anheuser-busch-heres-what-it-mean">ongoing strategy</a> to establish its presence in the U.S. One of its recent moves valued at $2 million was the purchase of <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">four craft breweries</a> from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
<h2 class="wp-block-heading">Social And Policy Implications</h2>
Federal legalization remains contentious as the outgoing Biden administration failed to reschedule cannabis and remove it from the&nbsp;<a href="https://www.benzinga.com/topic/controlled-substances-act" target="_blank" rel="noreferrer noopener">Controlled Substances Act</a>&nbsp;(CSA), which was <a href="https://www.benzinga.com/markets/cannabis/24/11/41752800/kamala-harris-promises-to-legalize-recreational-marijuana-in-groundbreaking-instagram-post" target="_blank" rel="noreferrer noopener">promised to voters</a>&nbsp;on a regular basis.
Now cannabis advocates are waiting to see what President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a> will do on that score. He too <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">has said</a> he'd reschedule cannabis.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42710061/cannabis-reform-2024-the-year-of-all-talk-and-no-action">Cannabis Reform 2024: The Year Of All Talk And No Action</a></li>
</ul>
Photo: MexChriss/Shutterstock.com

Cannabis In 2025: Inside America's Social, Economic, Wellness Transformation

Comments

Tilray Brands

Noticias

Últimas noticias sobre Tilray Brands (NASDAQ:TLRY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL